Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PMF”

70 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 70 results

Testing effectiveness (Phase 2)Study completedNCT03136185
What this trial is testing

Bomedemstat (IMG-7289/MK-3543) in Participants With Myelofibrosis (IMG-7289-CTP-102/MK-3543-002)

Who this might be right for
MyelofibrosisPost-polycythemia Vera Myelofibrosis (PPV-MF)Post-essential Thrombocythemia Myelofibrosis (PET-MF)+1 more
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) 90
Large-scale testing (Phase 3)Not Yet RecruitingNCT07357727
What this trial is testing

Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

Who this might be right for
Primary Myelofibrosis (PMF)Post-polycythemia Vera Myelofibrosis (PPV-MF)Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Novartis Pharmaceuticals 460
Testing effectiveness (Phase 2)Study completedNCT00509899
What this trial is testing

Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

Who this might be right for
MyelofibrosisPolycythemia VeraThrombocytosis
Incyte Corporation 154
Early research (Phase 1)Ended earlyNCT04637009
What this trial is testing

TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms

Who this might be right for
Acute Myeloid LeukemiaMyeloproliferative NeoplasmMyelodysplastic/Myeloproliferative Neoplasm
Astex Pharmaceuticals, Inc. 20
Large-scale testing (Phase 3)Study completedNCT03952039
What this trial is testing

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib

Who this might be right for
Primary MyelofibrosisPost-Polycythemia VeraMyelofibrosis
Celgene 202
Testing effectiveness (Phase 2)WithdrawnNCT04629651
What this trial is testing

Captopril Use on the Degree of Marrow Fibrosis in Bone Marrow Fibrosis/Myeloproliferative Neoplasms

Who this might be right for
Bone Marrow FibrosisMyeloproliferative Neoplasm
Case Comprehensive Cancer Center
Not applicableStudy completedNCT01956799
What this trial is testing

Identification of Mechanism in the Erythroid Response in Patients With Myelodysplasia Undergoing Chelation Therapy

Who this might be right for
MyelodysplasiaMyelofibrosisAplastic Anemia
Fondazione Italiana Sindromi Mielodisplastiche-ETS 100
Testing effectiveness (Phase 2)Ended earlyNCT02226172
What this trial is testing

Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib

Who this might be right for
Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
Pfizer 21
Testing effectiveness (Phase 2)Study completedNCT01423851
What this trial is testing

Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF

Who this might be right for
Primary MyelofibrosisPost-Polycythemia Vera MyelofibrosisPost-Essential Thrombocythemia Myelofibrosis
NS Pharma, Inc. 77
Testing effectiveness (Phase 2)Study completedNCT02966353
What this trial is testing

Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients.

Who this might be right for
Primary MyelofibrosisPost-Polycythemia Vera-MyelofibrosisPost-Essential Thrombocythemia Myelofibrosis
Novartis Pharmaceuticals 51
Testing effectiveness (Phase 2)Looking for participantsNCT06770842
What this trial is testing

Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis

Who this might be right for
Primary Myelofibrosis (PMF)Post Polycythemia Myelofibrosis (PPV MF)Post Essential Thrombocythaemia Myelofibrosis (PET-MF)
The University of Hong Kong 20
Testing effectiveness (Phase 2)Looking for participantsNCT05835466
What this trial is testing

Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)

Who this might be right for
Myelofibrosis (PMF)Post Essential Thrombocythemia Myelofibrosis (ET-MF)Post Polycythemia Vera Related Myelofibrosis (PV-MF)
Icahn School of Medicine at Mount Sinai 26
Testing effectiveness (Phase 2)UnknownNCT01298934
What this trial is testing

LBH589 (Panobinostat) for the Treatment of Myelofibrosis

Who this might be right for
Primary MyelofibrosisPolycythemia Vera, Post-Polycythemic Myelofibrosis PhasePost-Essential Thrombocythemia Related Myelofibrosis
Ronald Hoffman 22
Early research (Phase 1)Study completedNCT00910728
What this trial is testing

Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases

Who this might be right for
Primary Myelofibrosis (PMF)Post-Polycythaemia VeraEssential Thrombocythaemia Myelofibrosis
AstraZeneca 65
Testing effectiveness (Phase 2)Study completedNCT01644110
What this trial is testing

Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF

Who this might be right for
Primary MyelofibrosisSecondary MyelofibrosisPMF+3 more
University of Ulm 96
Testing effectiveness (Phase 2)UnknownNCT04878003
What this trial is testing

Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis

Who this might be right for
Primary Myelofibrosis (PMF)Post-Polycythemia Vera Myelofibrosis (Post-PV-MF)Post-Essential Thrombocythemia Myelofibrosis (Post-ET-MF)
Kartos Therapeutics, Inc. 52
Testing effectiveness (Phase 2)Ended earlyNCT01668173
What this trial is testing

HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET

Who this might be right for
Myeloproliferative Neoplasms
Memorial Sloan Kettering Cancer Center 7
Early research (Phase 1)Study completedNCT01317875
What this trial is testing

Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)

Who this might be right for
Myelofibrosis
Incyte Corporation 69
Testing effectiveness (Phase 2)Study completedNCT01340651
What this trial is testing

Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients

Who this might be right for
Myelofibrosis
Incyte Corporation 41
Testing effectiveness (Phase 2)Study completedNCT01348490
What this trial is testing

Ruxolitinib (INCB018424) in Participants With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis (PPV-MF)

Who this might be right for
MPN (Myeloproliferative Neoplasms)
Incyte Corporation 66
Load More Results